Lamotrigine-lnduced stevens-johnson syndrome: Demonstration of specific lymphocyte reactivity in vitro

Dermatology

Volumn 195, Issue 1, 1997, Pages 60-64

  Sachs, B ^a   Ronnau A C ^a   von Schmiedeberg, S ^a,b   Ruzicka, T H ^b   Gleichinann, E ^a   Schuppe, H C ^b  

^a Med Inst of Environmental Hygiene   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Lamotrigine; Lymphocyte transformation test; Stevens Johnson syndrome

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; FOCAL EPILEPSY; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION TEST; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SKIN BIOPSY; STEVENS JOHNSON SYNDROME;

ADULT; ANTICONVULSANTS; CONCANAVALIN A; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; LIVER; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; RISK FACTORS; STEVENS-JOHNSON SYNDROME; TRIAZINES; VALPROIC ACID;

EID: 1842369622     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000245690     Document Type: Article

References (32)

1. Messenheimer JA: Lamotrigine. Clin Neuro-pharmacol 1994;17:548-559.
2. Fitton A. Goa KL: Lamotrigine: An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995:50:691-713.
3. Binnie CD: The efficacy of lamotrigine. Rev Contemp Pharmacother 1994:5:115-122.
4. Timmings PL. Riehens A: Lamotrigine in primary generalized epilepsy (letter). Lancet 1992:339:1300-1301.
5. Cocito L. Maffini M. Loch C: Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res 1994;19:123-127.
6. Meldrum B. Leach M: The mechanisms of action of lamotrigine. Rev Contemp Pharmacother 1994:5:107-114.
7. Sterker M. Berrouschot J. Schneider D: Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther Toxicol 1995:33:595-597.
8. Srinivasan J. Riehens A: The safety and tolerability of lamotrigine. Rev Contemp Phartnaco-thcr 1994:5:147-151.
9. Riehens A: Safety of lamotrigine. Epilepsia 1994;35:S37-S40.
10. Beils T: Clinical use of lamotrigine. Seizure 1992:1:3-6.
11. D'Arcy PF: Drug reactions and interactions. Int PharmJ 1993:7:140-141.
12. Yuen AWC. Land G. Weatherley BC. Peck AW: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992: 33:511-513.
13. Berg PA. Becker EW: Zellularc Immunreak-tionen bei Patienten mit medikamentosen Nebenwirkungen: Diagnostische Relevanz des Lymphozytentransformationstests: in Merk HF (ed): Allergische und pseudoallergische Arzncimittelreaktionen. Berlin. Blackwell Wis-senschaft, 1993: pp 101-118.
14. Roujeau J-C. Stem RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994: 331:1272-1285.
15. Schopf E. Stiihmer A. Rzany B, Victor N. Zent-graf R. Kapp JF: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 1991:127:839-842.
16. Assier H. Bastuji-Garin S, Revuz J. Roujeau J-C: Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995:131: 539-543.
17. Bastuji-Garin S. Rzany B. Stern RS. Shear NH. Naldi L. Roujeau J-C: Clinical classification of cases of toxic epidermal necrolysis. Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993:129:92-96.
18. Cote B. Wechsler J. Bastuji-Garin S. Assier H, Revuz J. Roujeau J-C: Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995:131: 1268-1272.
19. Roujeau J-C. Kelly JP. Naldi L, Rzany B. Stern RS, Anderson T. Auquier A. Bastuji-Garin S, Correia O. Locati F. Mockenhaupt M. Paolelti C. Shapiro S. Shear N. Schopf E. Kaufman DW: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995:333:1600-1607.
20. Herd M. Merk HF: Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995:105:95-98.
21. Rassmussen JE: Erythema multiforme. Arch Dermatol 1995:131:726-729.
22. Patterson R. Miller M, Kaplan M. Doan T. Brown J. Detjen P. Grammer LC. Greenberger PA. Hogan BM. Latall J. Lowenthal M. Pon-gracic J. Sonenthal K. Zeiss CR: Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: Experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994:73:27-34.
23. Stejskal VDM. Olin RG. Forsbeck M: The lymphocyte transformation test for diagnosis of drug-induced occupational allergy. J Allergy Clin Immunol 1985:77:411-126.
24. Mauri-Hellweg D. Bettens F. Mauri D. Brander C. Hunziker T. Pichler WJ: Activation of drug-specific CD4+ and CD8+ Tcells in individuals allergic to sulfonamides, phenytoin and car-bamazepine. J Immunol 1995:155:2-11.
25. Uetrecht JP: The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992:24:299-366.
26. Maria VAJ. Victorino RMM: Lymphocyte proliferative response to drugs: Analysis of the value of a 24-well lymphocyte culture system. Toxic In Vitro 1994:8:1041-1044.
27. Roujeau JC, Albengres E. Moritz S. Piacentino A. Cuny M. Reuz J. Touraine R: Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985:78:22-24.
28. Brattig NW. Diao G-J. Berg PA: The specificity of the lymphocyte transformation test in a patient with hypersensitivity reactions to pyrazolone compounds: A 10-week follow-up study before and after rechallenge. Eur J Clin Pharmacol 1988:35:39-45.
29. Wolf P: New antiepileptic drugs already registered. Epilepsia 1994;35:S22-S24.
30. O'Donoghue MF. Sander JWAS: Lamotrigine versus carbamazepine in epilepsy (letter). Lancet 1995:345:1300.
31. Betts T, Goodwin G. Withers RM. Yuen AWC: Human safety of lamotrigine. Epilepsia 1991: 32:S17-S21.
32. Turnbull DM. Rawlins MD. Weightman D. Chadwick DW: Plasma concentrations of sodium valproate: Their clinical value. Ann Neurol 1983:14:38-42.